Mitsubishi Tanabe Pharma Corporation
Medium-Term Management Plan 11-15

New Value Creation

President & Representative Director
Michihiro Tsuchiya
Key Concept

Review of Medium-Term Management Plan 08-10

Medium-Term Management Plan 11-15

Becoming a Company that Can Continue to Create New Value

Strategic Challenges

1. Bolstering Our Ability to Discover New Drugs
2. Advancing Domestic Operations, Centered on New Products
4. Accelerating Operational and Structural Reforms

Numerical Targets

Together with Society
Mitsubishi Tanabe Pharma will move on to a new growth stage under the Medium-Term Management Plan 11-15.

The key concept of that new stage is **New Value Creation**. Guided by that concept, we will become a company that can continue to create new value.

We will build a management foundation for the discovery and global provision of new drugs that respond to unmet medical needs, and we will strive to contribute to improving the quality of life for large numbers of patients around the world.

This is our mission: providing a wide-range of value to society.

* Unmet medical needs: Medical needs for which there are no effective treatments or drugs
We strive to be a global research-driven pharmaceutical company that is trusted by communities.

Our Plan for 2015

We have a product pipeline that responds to unmet medical needs around the world.

We have the capacity to implement stable investment in R&D.

We are moving ahead with the establishment of a foundation for global development.
Review of Medium-Term Management Plan 08-10
## Results of Medium-Term Management Plan 08-10 and Ongoing Challenges: 1

<table>
<thead>
<tr>
<th>Results</th>
<th>Challenges</th>
</tr>
</thead>
</table>
| **Enhancing the company’s domestic sales presence** | • Steady penetration and nurturing of new products  
• Establishing an efficient and effective information provision system |
| • Enhanced the value of Remicade  
• Enhanced specialized fields (Remicade, cerebral)  
• In-licensed Kremezin and Lexapro | |
| **Steady progress in key development projects** | • Obtaining approval as rapidly as possible for drugs in late-stage development in Japan and overseas  
• Enhancing pipeline that will support sustained growth  
• Rapid establishment of POC*1  
• Ongoing LCM*2 for priority products  
• Strengthening discovery capabilities for responding to unmet medical needs |
| • Remicade:  
  Acquired approval for psoriasis, ankylosing spondylitis, and ulcerative colitis and for increased dosage for RA  
  Filed NDAs for Simponi, Telavic, Imusera  
  Moved MP-513 and TA-7284 to subsequent development stages  
  Launched FTY720 in Europe and U.S. (Novartis) | |
| **Progress in developing overseas pharmaceutical operations** | • Establishing operational foundation in the U.S.  
• Accelerating operational expansion in China |
| • Established sales companies in the U.S. and China  
• Expanded countries where argatroban is sold in Europe | |

*1. Proof of concept: Establishment of efficacy and safety in humans  
*2. Life cycle management: Contributing to more patients through additional indications, etc.
## Review of Medium-Term Management Plan 08-10

### Results of Medium-Term Management Plan 08-10 and Ongoing Challenges: 2

<table>
<thead>
<tr>
<th>Results</th>
<th>Challenges</th>
</tr>
</thead>
</table>
| **Progress in generic operations** | • Established operational foundation  
• Established Tanabe Seiyaku Hanbai  
• Took an equity position in Choseido Pharmaceutical  
• Expanded the number of products handled | • Bolstering lineup with launch of large-scale products  
• Nurturing products through cooperation within the Group  
• Expanding operations with consideration for strategic cooperation |
| **Creating an efficient organization and cost structure** | • Generated cost synergies  
(cumulative total of ¥23.5 billion)  
• Consolidated functional subsidiaries  
(production services)  
• Consolidated research bases, Osaka head office, training centers | • Further functional and worksite reorganization (production, research, head office, branches, etc.)  
• Strategic nurturing of organizational systems and human resources |
| **Numerical targets** | • Net sales  
Plan: ¥460.0 billion → Results: ¥409.5 billion  
• Operating income  
Plan: ¥95.0 billion → Results: ¥76.5 billion  
• Did not achieve numerical targets for net sales or operating income | • Implementing additional measures to achieve numerical targets, preparing for alternate scenarios |

**Dynamic Synergy**, the key concept of the Medium-term Management Plan 08-10, generated steady results linked to future growth.
Medium-Term Management Plan 11-15

Becoming a “Company that Can Continue to Create New Value”

Strategic Challenges

1. Bolstering Our Ability to Discover New Drugs
2. Advancing Domestic Operations, Centered on New Products
4. Accelerating Operational and Structural Reforms

Numerical Targets
Becoming a “Company that Can Continue to Create New Value”
**Becoming a “Company That Can Continue to Create New Value”**

**View of External Management Environment**

<table>
<thead>
<tr>
<th>Industrially developed markets (Japan / U.S. / Europe)</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Markets receptive to innovative medicine</td>
</tr>
<tr>
<td>Market scale: large</td>
</tr>
<tr>
<td>Growth rate: low</td>
</tr>
<tr>
<td>- Measures to control health care to limit social insurance expenditures (focus on medical cost performance)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Emerging markets (China, etc.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Markets in which the level of medical treatment is rising rapidly in conjunction with economic growth</td>
</tr>
<tr>
<td>Market scale: rapidly expanding</td>
</tr>
<tr>
<td>Growth rate: high</td>
</tr>
<tr>
<td>- Possible to implement development in a short period of time for products that have been approved in Europe / U.S.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Increasing difficulty in drug discovery</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Progress in science and technology; more-complicated, more-advanced disease mechanisms</td>
</tr>
<tr>
<td>- Rising development costs, rising approval hurdles</td>
</tr>
</tbody>
</table>

- **Ongoing polarization in pharmaceuticals**
  “Innovative, high-priced drugs” and “commodity, low-priced drugs.”

- **Convergence toward global mega pharmaceutical companies, specialty pharmaceutical companies, and mega generic pharmaceutical companies.**
  New global drugs: Key points are the ability to discover new drugs and massive upfront investment
  Specialty drugs: Key point is bolstering competitiveness through area specialization
  Generic drugs: Key points are reliability and cost competitiveness
Becoming a “Company that Can Continue to Create New Value”

Overview of Medium-Term Management Plan 11-15

Key Concept

New Value Creation

Period

April 2011 to March 2016 (five years)

Objectives that Will be Realized under the Medium-Term Management Plan 11-15

Becoming a company that can continue to create new value

Building a foundation for future growth

- Taking on the challenge of unmet medical needs
- Discovering drugs and building a foundation to provide them around the world
- Investing aggressively in future growth

Steadily nurturing and providing new products and priority products, centered on Remicade

Fiscal 2015 Numerical Management Objectives

Net sales: ¥500.0 billion
Operating income: ¥100.0 billion
Creating a sustained growth spiral by continually reinvesting profits

Continual reinvestment

Bolstering our ability to discover new drugs

Building a foundation for the expansion of overseas operations

- Investment to enhance pipeline
- Investment to rapidly nurture new products
- Investment to strengthen foundation for overseas operations

Increasing our revenue / profit generating capacity

Advancing domestic operations, centered on new products

Accelerating operational and structural reforms

- Revenues / profits from existing businesses
- Maximizing revenues / profits from new products
- Expanding scale of and revenues / profits from overseas businesses
- Large-scale product royalty revenues
- Low cost operations

Becoming a “Company that Can Continue to Create New Value”

Creating a Sustained Growth Spiral
By continually launching new drugs, we will reform our revenue / profit structure so that overall profits are centered on priority products and new products.
**Medium-Term Management Plan 11-15: Strategic Challenges**

1. **Bolstering Our Ability to Discover New Drugs**
2. **Advancing Domestic Operations, Centered on New Products**
3. **Building a Foundation for the Expansion of Overseas Operations**
4. **Accelerating Operational and Structural Reforms**

Our Plan for 2015

- **Bolstering Our Ability to Discover New Drugs**
- **Building a Foundation for the Expansion of Overseas Operations**
- **Advancing Domestic Operations, Centered on New Products**
- **Accelerating Operational and Structural Reforms**

Aggressive investment in growth
Bolstering Our Ability to Discover New Drugs

Discovering new drugs that respond to unmet medical needs
### Overview of New Drug Launches

#### Areas

<table>
<thead>
<tr>
<th>Areas</th>
<th>Principal target diseases in research stage to early development stage</th>
<th>Products expected to be launched under Medium-Term Management Plan 11-15*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marketing franchise areas</td>
<td></td>
<td>Acquisition of POC Late-stage Launch LCM</td>
</tr>
<tr>
<td>Autoimmune diseases</td>
<td>● RA, Crohn’s disease, psoriasis, etc.</td>
<td>MP-146  MCI-196</td>
</tr>
<tr>
<td>Kidney diseases</td>
<td>● Complications of dialysis</td>
<td>TA-7284  MP-513</td>
</tr>
<tr>
<td>Diabetes (including complications)</td>
<td>● Chronic kidney disease</td>
<td></td>
</tr>
<tr>
<td>New disease areas</td>
<td>● Multiple Sclerosis</td>
<td>MP-214  ACREF  Radicut</td>
</tr>
<tr>
<td>Neurological disorders, etc.</td>
<td>● Schizophrenia, dementia, pain, etc.</td>
<td></td>
</tr>
<tr>
<td>Other areas</td>
<td></td>
<td>BK-4SP (vaccine)  Telavic  Talion  Maintate</td>
</tr>
</tbody>
</table>

* Including additional indications

#### In-licensed products

<table>
<thead>
<tr>
<th>Launch in fiscal 2016 or thereafter</th>
</tr>
</thead>
<tbody>
<tr>
<td>TRK-820 (kidney diseases: refractory pruritus)</td>
</tr>
</tbody>
</table>

Development region

- Europe / U.S.
- Japan
Bolstering Our Ability to Discover New Drugs

Enhancing Pipeline for Sustained Growth

Objectives

- Products advancing to late-stage development: 8 products (fiscal 2011-2015)
- Products starting clinical trials: 3 products / year (fiscal 2015 objective)

- Accelerate acquisition of POC by consolidating discovery and early stage clinical trials
- Advancing in-licensing and alliances
- Bolstering global development function (strengthen four part system: U.S., Europe, China, Japan)
- Strengthen producing function for clinical trial drugs to respond appropriately to increase in number of drugs in development

* Japan: Simponi, Telavac, Imusera, ACREF, MP-513, TA-7284, MP-214, BK-4SP
Overseas: MCI-196, MP-146
Bolstering Our Ability to Discover New Drugs

Bolstering the Drug Discovery Function

- **Target discovery**
  - Target compounds linked to unmet medical needs

- **Compound optimization**
  - One of our strengths
  - Increasing the speed of the optimization process
  - Medicinal chemistry
  - Organic synthesis

- **Evaluation**
  - Effectiveness
  - Pharmacokinetics
  - Safety

- **Advancing to clinical trials:**
  - 3 products / year
  - Development compounds

- **Needs / targets from clinical practice**
  - Needs / targets from clinical practice

- **Highly original compounds**
  - Differentiated biologics

- **Compounds that respond to unmet medical needs**

- **Academic institutions in clinical development**
  - Search for candidates for CKD, autoimmune diseases, neurological conditions, pain, etc; search for markers; investigate concepts

- **Venture companies**
  - Taking on the challenge of new chemical areas*
    - Low-molecular versions of macromolecular pharmaceuticals, etc.
  - Securing new biologics technologies
    - Development in the fields of vaccines and orphan drugs

* Discovery technologies for target molecules to which there is not a sufficient response with existing low-molecule compounds or antibodies.
**Continued pipeline strengthening in marketing franchise areas**

<table>
<thead>
<tr>
<th>Autoimmune diseases</th>
<th>Diabetes / kidney diseases</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Remicade, Simponi</strong></td>
<td><strong>MP-513, TA-7284</strong></td>
</tr>
<tr>
<td>Continued implementation of LCM</td>
<td>Rapid launch</td>
</tr>
<tr>
<td><strong>MT-1303 (successor to Imusera)</strong></td>
<td>Advancing measures to promote rapid market penetration to maximize value</td>
</tr>
<tr>
<td>Development for autoimmune diseases</td>
<td><strong>MCI-196, MP-146</strong></td>
</tr>
<tr>
<td><strong>Early development stage products, research stage products</strong></td>
<td>Development in Europe / U.S. markets</td>
</tr>
<tr>
<td><strong>RA, psoriasis, orphan diseases, etc.</strong></td>
<td><strong>Early development stage products, research stage products</strong></td>
</tr>
<tr>
<td></td>
<td>Strengthening initiatives in chronic kidney disease, diabetes complications, etc.</td>
</tr>
</tbody>
</table>

* Product areas that strengthen our marketing foundation
Advancing Domestic Operations, Centered on New Products

Continuing to provide products that have value with reliable information
## Advancing Domestic Operations, Centered on New Products

### Growth Drivers in Domestic Operations

#### Medium-Term Management Plan 11-15

<table>
<thead>
<tr>
<th>New products</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Simoni</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Imusera</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Telavic</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Lexapro</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>MP-513</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>TA-7284</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>MP-214</td>
<td></td>
</tr>
</tbody>
</table>

#### Priority products

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Remicade</td>
<td>Increased dosage for Crohn’s disease</td>
</tr>
<tr>
<td>Talion</td>
<td>Pediatric</td>
</tr>
<tr>
<td>Radicut</td>
<td>ALS</td>
</tr>
<tr>
<td>Maintate</td>
<td>Heart failure</td>
</tr>
</tbody>
</table>

* Under development by Janssen Pharmaceutical
Provide lineup of drugs that respond to unmet medical needs, together with **reliable information based on global evidence, to as many patients as possible.**

**Remicade**
- Further enhance product presence
- High-quality information provision activities as a leading company

**New products / existing priority products**
- New products: focus on promoting appropriate usage
- Priority products: Steady promotion
- Post-marketing development of products: Nurturing together with patients, medical professionals
**Indications:**

Various inflammatory diseases

Reduces chronic pain and distress suffered by patients and makes it possible for them to enjoy the same lifestyles as healthy people.

<table>
<thead>
<tr>
<th>Indications</th>
<th>No. of patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crohn’s disease</td>
<td>30,000</td>
</tr>
<tr>
<td>RA</td>
<td>250,000 (patients taking MTX)</td>
</tr>
<tr>
<td>Behcet’s disease (ocular)</td>
<td>10,000 (uveitis)</td>
</tr>
<tr>
<td>Psoriasis</td>
<td>100,000</td>
</tr>
<tr>
<td>Ankylosing spondylitis</td>
<td>2,000</td>
</tr>
<tr>
<td>Ulcerative colitis</td>
<td>110,000</td>
</tr>
</tbody>
</table>

**Positioning in treatment**

As first-in-class, best-in-class biologics, the first choice for various inflammatory diseases, including orphan diseases

**Future additional indications**

Pediatric ulcerative colitis, special types of Behcet’s disease, severe Kawasaki disease

**Sales system / policies**

Strive to enhance quality and quantity of appropriate usage in formation provision through cooperation between MRs specializing in Remicade and general MRs.
Indications: RA
No. of patients: 500,000

Treatment can be undertaken with peace of mind, with administration once every four weeks, under the doctor’s supervision, in conjunction with patient hospital visits.

Value for patients

Subcutaneous injection that is the first choice in RA treatment
High effectiveness and treatment continuity

Positioning in treatment

Sales system / policies

Drawing on the marketing base and reputation for reliability established with Remicade, we will work to promote its use on a foundation of appropriate usage and effectiveness (co-marketing with Jannsen Pharmaceutical)
Indications: MS
No. of patients: 14,000

Offers superior treatment effectiveness due to new mechanism of action discovered by the Company. It is the world’s only oral formulation for MS.

It lowers the psychological and physical burden faced by patients being treated with existing self injection methods.

Acquisition of approval in more than 50 countries

Positioning in treatment
Provides a new choice in drug treatment of MS, where unmet medical needs remain.

Sales system / policies
Through the use of global prescription data and the implementation of domestic all-patient survey, we will accumulate evidence and earn the trust of prescribing doctors.
Indications: Chronic hepatitis C

No. of patients: 400,000 to 500,000 / year

No. of 2-drug combination therapy patients: 20,000 to 25,000 / year

Expected to be highly effective, even for patients for whom existing treatments have not been effective.

Treatment period reduced by half, lessening the treatment burden borne by patients.

Status of overseas approvals
- **U.S.** (May 2011)
- **Canada** (August 2011)
- **Europe** (September 2011)

Positioning in treatment
Basic treatment agent of chronic hepatitis C.
Working to expand indications to genotype 2 and to increase combination therapy.

Sales system / policies
In safety management operations, we will work in cooperation with hepatologists and dermatologists at medical institutions implementing an all-patient survey, and we will promote 3-drug combination therapy.
**Psychiatric and Neurological Conditions: Lexapro**

**Value for patients**

**Indications: Depression / depressive symptoms**

**No. of patients: 1 million**

Supports the return to society, the most important factor for patient QOL, with high treatment continuity

Has been administered to more than 230 million people worldwide, top share among SSRIs

**Positioning in treatment**

Good balance between effectiveness and tolerability. Simple administration. Therefore, first line drug for depression, with high treatment continuity.

**Sales system / policies**

Comarketing with Mochida Pharmaceutical, which is the license holder in Japan. Will aim to achieve top share among SSRIs* through co-promotion with Yoshitomi-yakuhin, which has a top class presence in the psychiatric area in Japan.

* SSRI: selective serotonin reuptake inhibitor
## Indications: Type 2 diabetes mellitus

### No. of patients with diabetes: 8.9 million

MP-513 and TA-7284 are oral drugs with new mechanism that can be administered in combination and are available for a wide range of patients. They can control blood sugar with a high degree of safety.

<table>
<thead>
<tr>
<th>Status of overseas development</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TA-7284</strong></td>
</tr>
<tr>
<td>Planning to file NDA in 2012</td>
</tr>
<tr>
<td>Johnson &amp; Johnson</td>
</tr>
</tbody>
</table>

### Positioning in treatment

- **MP-513**: Among DPP4 inhibitors, which are growing rapidly, optimal drug for initial treatment, with both effective blood sugar control and ease-of-use.

- **TA-7284**: Makes possible new treatment strategy for diabetes (SGLT2 inhibitor)

### Sales system / policies

Will implement marketing strategy to nurture these two drugs as standards in diabetes treatment. (Will consider combination drug.)
Advancing Domestic Operations, Centered on New Products

Information Provision System that Meets Diverse Customer Needs

"T-Shaped" Marketing System

Bolster cooperative work between MRs and specialized MRs

On-demand information provision system

- Deeper information provided
  - Evidence, appropriate usage information for new drugs
- Information provision using ICT*
- Cross media utilization

Needs by type of customers

- Doctors
- Patients
- Pharmacists

Inquiries / needs
Appropriate usage
Two-way
Distribution

Product information database

- ICT use
- Establishment of two-way network
- New convention system using network

* ICT: information and communication technology
3 Building a Foundation for the Expansion of Overseas Operations

Providing drugs that have value to many patients around the world
Building a Foundation for the Expansion of Overseas Operations

Area Strategy

**Industrially developed markets**
- Innovative treatment methods with medical cost performance

**Emerging markets**
- Development in Asia, centered on China

**Promotion of products suitable for late-stage development and sales in-house**
- (kidney diseases, critical / orphan diseases, etc.)
- Following approval in U.S. / Europe, expand to emerging markets

**For drugs other than those above (circulatory and metabolism diseases, etc.), after POC is acquired we will work to rapidly maximize product value, using alliances, etc.**

**Following approval in Japan, expand to emerging markets**
- (circulatory and metabolism diseases, etc.)

**Promotion of products meeting distinctive medical needs in China / Asia**
- (chronic hepatitis, infectious diseases)

**Fiscal 2011**
- Overseas Sales

**Fiscal 2015**
- Royalty revenues (Gilenya, TA-7284)
Building a Foundation for the Expansion of Overseas Operations

New Products, Development Products for Expansion of Overseas Operations

<table>
<thead>
<tr>
<th>Medium-Term Management Plan 11-15</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Industrially developed markets (U.S. / Europe)</strong></td>
<td></td>
</tr>
<tr>
<td>MCI-196</td>
<td>Hyperphosphatemia</td>
</tr>
<tr>
<td>MP-146</td>
<td>Chronic kidney disease (Europe, U.S.)</td>
</tr>
<tr>
<td>MT-1303</td>
<td>MS (POC)</td>
</tr>
<tr>
<td>TRK-820</td>
<td>In-licensed</td>
</tr>
</tbody>
</table>

| **Emerging markets (China)** | |
| Radicut | Acute stage of cerebral infarction |
| MP-424 | Start of phase 3 | Chronic hepatitis C |
| MP-513 | Start of phase 3 | Type 2 diabetes mellitus |
| MP-214 | Start of phase 3 | Schizophrenia |
Building a Foundation for the Expansion of Overseas Operations

Industrially Developed Markets (U.S. / Europe)

Basic Strategies

- Renal disease drugs (MCI-196, MP-146): In-house development focused on specialist doctors.

- Establish new focus areas in addition to renal diseases (autoimmune diseases, etc.: MT-1303, etc.), bolster development system

- Aggressively secure management resources (functions, systems, products, technologies) to bolster and expand operating base (TRK-820, etc.)

- Strengthen product pipeline, with renal disease area positioned as beachhead for business development in the U.S.

- Establish sales bases in 5 European countries (In addition to the U.K. and Germany, newly establish in-house sales bases in France, Italy, Spain)
  - Expand sales by acquiring approval in new regions and launching argatroban.
Emerging Markets (China, Asia)

Basic Strategies

• Rapidly launch products that have been approved in industrially developed market
• Aggressively in-license products that match characteristics / needs of each market

China
• Build in existing foundation with flexible yet optimal production, development, and sales systems that match the Chinese market. Enhance market presence.
• Work to accelerate development and achieve rapid launch
  • Accelerate development of MP-424, aiming for rapid launch
  • Start rapid development of MP-513, MP-214, etc., launch Radicut
  • Accelerate initiatives such as the introduction of products in the area of hepatitis treatment

Asia*
• Build an independent growth organization that maximizes business value

* South Korea, Taiwan, Southeast Asia
4 Accelerating Operational and Structural Reforms

Value Creation

Becoming a Company that Can Continue to Create New Value
### Accelerating Operational and Structural Reforms

**Accelerating Worksite, Structural, and Organizational Reforms**

#### Medium-Term Management Plan 11-15

<table>
<thead>
<tr>
<th>Base reorganization</th>
<th></th>
<th>Further consolidation / reorganization of functional bases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research facilities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Production</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Head office</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Building streamlined systems and bolstering organizations / human resources that support them

- **Research facilities**
  - Research facility reorganization
  - Construction of GLP facilities
  - Expansion of CMC research facilities
  - CMC clinical drug facility expansion, etc.

- **Production**
  - Construction of new building for solid formulations
  - Construction of new building for raw materials

- **Head office**
  - Osaka head office building construction / relocation
  - Tokyo head office building (Nihonbashi, Sanban-cho) reorganization / relocation
  - Kashima office reorganization

- **Other**
  - Establishment of new company for plasma derivative operations
  - Reorganization of other operations
  - Rearrangement of products handled
  - Steady implementation of improvement plan related to quality control problem
  - Strengthening / enhancing organizations, human resources
  - Strengthen human resources / organizations that can contribute to global business development

---

*Note: The image contains a table and a diagram illustrating the plan for medium-term management.*
From the perspective of disease prevention, contribute to society by supplying vaccines

- Mitsubishi Tanabe Pharma has the highest vaccine sales in Japan

- Bolster domestic foundation, centered on relationship with BIKEN*
  - Based on the sales foundation established to date, strive to maximize value as the top domestic brand, such as through joint development of a combination vaccine for four diseases
  - Independently in-license competitive products / technologies, link to new product development, etc. based on cooperation with BIKEN

---

**Mitsubishi Tanabe Pharma**
- Bolstering marketing systems
- Cooperative ventures in development, etc.
- In-licensing of new products / technologies

**Contribute to society from the perspective of disease prevention**

**BIKEN**
- Top domestic vaccine brand
- Stable vaccine development / production system

* The Research Foundation for Microbial Diseases of Osaka University
Provide “Reliable Generics” that leverage the strengths of the Group’s organizational foundation (new drugs, specialized areas)

Business strategies

1. Maximize sales of large-scale new products through cooperation within the Group (Specialized areas of Tanabe Seiyaku Hanbai, Mitsubishi Tanabe Pharma, Yoshitomi yakuhin, etc.)
   ① Bolster cooperation with wholesalers and sales companies
   ② Establish marketing foundation with dispensing pharmacies
   ③ Strengthen activities in Group priority areas

2. Build framework for production optimization
   Cooperation with Choseido Pharmaceutical, which will handle production

3. Work to enhance presence, with consideration for strategic cooperation

Fiscal 2015 sales target: ¥50.0 billion
Numerical Targets
## Fiscal 2015 Numerical Targets

<table>
<thead>
<tr>
<th></th>
<th>Fiscal 2011 forecasts</th>
<th>Fiscal 2015 objectives</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Net sales</strong></td>
<td>¥405.0 billion</td>
<td>¥500.0 billion</td>
</tr>
<tr>
<td><strong>Operating income</strong></td>
<td>¥68.0 billion</td>
<td>¥100.0 billion</td>
</tr>
<tr>
<td><strong>R&amp;D expenses</strong></td>
<td>¥69.0 billion</td>
<td>¥80.0 billion</td>
</tr>
<tr>
<td><strong>Overseas sales ratio</strong></td>
<td>6%</td>
<td>15%+</td>
</tr>
</tbody>
</table>

*On an operating income basis, we are aiming for an overseas sales ratio of 40% in fiscal 2015.*
Aggressive up-front investment to bolster foundation for sustained growth and expand operations

Total investment

More than ¥100.0 billion over a five-year period
(capital investment, in-licensing expenses)

Details of major capital investment

- Consolidate / bolster production function
- Consolidate / bolster research function
- Build Osaka head office
- Restructure IT platform

R&D expenses

¥75.0 billion to ¥80.0 billion / year
(including above in-licensing expenses)

Advance strategic cooperation
The Company’s basic policy calls for providing a stable, return to shareholders while striving to maximize enterprise value by aggressively investing in future growth.

Under this medium-term management plan, in addition to profit growth, we will strive to raise the consolidated dividend payout ratio (prior to amortization of goodwill) to 40% and expand shareholder return.
Together with Society
Together with Society

Contributing to KAITEKI Society

As core health care company in MCHC Group, contribute to realization of KAITEKI society

Contribute to realization of KAITEKI society

Using technologies/products within the MCHC Group
- Testing technology
- Discovery support
- Diagnosis systems

Orchestrating within MCHC Group
- Medical LEDs
- Medical materials
- Water for medical use

Contribute to raising patient QOL

Health care
Mitsubishi Tanabe Pharma

Functional products
Sustainability
Health
MCHC Group

Materials
Comfort
On a foundation of “regaining the trust of society” and “securing quality and safety,” we will be a company that fulfills its social mission—contributing to improvements in patients’ QOL by “manufacturing and providing pharmaceuticals.”
Fulfilling our social mission—Contributing to improvements in patients’ QOL
Continuing to be a good corporate citizen
Contributing to society through growth as a company

Fostering “social” sustainability

Patients

Medical professionals
- Doctors
- Pharmacists

Academics
- Universities

Stockholders
- Investors

Partners
- Wholesalers
- Suppliers

Local communities
- NPO

Mitsubishi Tanabe Pharma Corporation

Corporate philosophy / Our Vision / Corporate Behavior Charter

Reliability guarantee / control

Manufacturing

Development

Research

Marketing

Contributing to improvements in patient’s QOL

Together with Society

Contributing to the Sustainability of Society
New Value Creation

Becoming a “Company that Can Continue to Create New Value”
Mitsubishi Tanabe Pharma
Cautionary Statement

The statements contained in this presentation is based on a number of assumptions and belief in light of the information currently available to management of the company and is subject to significant risks and uncertainties. Actual financial results may differ materially from these forecasts depending on a number of important factors.